Dermatological effects of Curcuma species: a systematic review.
Sandra Maria BarbalhoH F de Sousa GonzagaG A de SouzaR de Alvares GoulartM L de Sousa GonzagaB de Alvarez RezendePublished in: Clinical and experimental dermatology (2021)
Curcuma and its derivatives are associated with anti-inflammatory and antioxidant activities in the skin. They exhibit beneficial effects in wound healing and prevention of chronic ultraviolet B damage and may prevent facial redness such as rosacea and flushing. This review aims to provide an up-to-date and rigorous synthesis of studies that demonstrated the clinical efficacy of curcuminoids in the skin. We evaluated studies published in the MEDLINE-PubMed/PMC (National Library of Medicine) databases, and followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for this review. This search included papers published in the past 10 years in controlled clinical trials, double-blind and randomized controlled studies, and case studies. The search resulted in 12 studies published in the past 10 years. Curcuma species (Curcuma longa and Curcuma aeruginosa) and curcumin were found to produce various dermatological effects, including influencing antioxidant and anti-inflammatory processes in the production of hyaluronan, increasing skin moisture, and reducing axillary hair growth. Curcuma was also found to reduce thickness, erythema, pruritus, burning and pain in psoriasis lesions and to improve radiodermatitis lesions. Our review results show that Curcuma species may play a role in skin health management and may exhibit various dermatological effects, thus it could be a new therapeutic arsenal for dermatology professionals. Nevertheless, more clinical trials should be conducted with humans to establish the optimum delivery method and dosages for different dermatological conditions.
Keyphrases
- anti inflammatory
- wound healing
- meta analyses
- clinical trial
- double blind
- soft tissue
- systematic review
- case control
- oxidative stress
- placebo controlled
- phase ii
- phase iii
- open label
- randomized controlled trial
- public health
- healthcare
- emergency department
- chronic pain
- quality improvement
- climate change
- radiation therapy
- study protocol
- risk assessment
- atopic dermatitis
- human health
- health information
- adverse drug
- deep learning